One such study should explore the treatment outcomes of GLP-1R agonists on the subjective experiences associated with the consumption of other addictive drugs
But the results tend to be more durable because the underlying metabolic drivers have changed, not just suppressed
Survodutide Dosing The SYNCHRONIZE Phase 3 trials use a modified escalation protocol designed to improve tolerability compared to Phase 2: Starting dose: Low dose with gradual increases Escalation: Extended titration period with flexibility Target doses: 3.6mg or 6.0mg weekly (SYNCHRONIZE-1) Pause option: Ability to temporarily stop dosing for GI symptoms Time to maintenance: Extended to reduce side effects The inclusion of a pause option in Survodutide trials reflects lessons learned from Phase 2 about the importance of allowing patient-directed tolerance management

Your provider will evaluate several other factors as well, including: History with weight management, especially prior weight-loss attempts Personal medical history Family medical history Age (only available for adults 18 or older) Semaglutide treatment is not recommended for the following individuals: Pregnant or breastfeeding women Those with a personal or family history of medullary thyroid carcinoma or MEN 2 Other medical conditions may affect whether you qualify for semaglutide
These tend to resolve without intervention and become less frequent as the body adapts to the medication
A few patients were forced to discontinue treatment if the symptoms persisted, and this was unusual